Related Experiment Video
Updated: Jul 29, 2026
08:32
Studying the Hypothalamic Insulin Signal to Peripheral Glucose Intolerance with a Continuous Drug Infusion System into the Mouse Brain
Published on: January 4, 2018
A transdermal delivery system for glipizide
H O Ammar1, H A Salama, M Ghorab
1Department of Pharmaceutical Technology, National Research Centre, Cairo, Egypt. husseinammar@hotmail.com
Current Drug Delivery
|July 20, 2006
Summary
This study developed a transdermal glipizide delivery system to improve type 2 diabetes treatment. Optimized formulations with cyclodextrin complexes and penetration enhancers showed sustained therapeutic efficacy and suppressed hyperglycemia in rats.
Area of Science:
- Pharmaceutical Sciences
- Dermatology
- Endocrinology
Background:
- Oral glipizide for type 2 diabetes presents bioavailability issues and risks of hypoglycemia and gastric problems.
- Transdermal drug delivery offers a potential alternative for improved patient compliance and safety.
Purpose of the Study:
- To develop and evaluate a transdermal glipizide delivery system for type 2 diabetes management.
- To enhance glipizide bioavailability and therapeutic efficacy through novel formulations.
Main Methods:
- Preparation of glipizide inclusion complexes with various cyclodextrins (beta-CyD, DM-beta-CyD, HP-beta-CyD, HP-gamma-CyD).
- Development of percutaneous formulations using different bases and penetration enhancers (e.g., propylene glycol, oleic acid, urea).
- In vitro release, ex vivo skin permeation, and in vivo efficacy studies in diabetic rats.
Main Results:
- Glipizide-cyclodextrin complexes significantly improved drug release and skin permeation.
- Carbopol gel formulations with propylene glycol, oleic acid, or urea demonstrated highest drug flux.
- In vivo studies confirmed sustained therapeutic efficacy for 48 hours and suppression of hyperglycemia.
Conclusions:
- A transdermal glipizide delivery system is feasible for type 2 diabetes treatment.
- Optimized formulations enhance drug delivery, efficacy, and patient compliance.
- This approach may improve the management of type 2 diabetes pathophysiology.
Related Concept Videos
01:26Oral Drug Delivery Systems: Continuous-Release Systems
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
01:18Transdermal Drug Delivery Systems
Transdermal drug delivery systems (TDDS) enable the controlled release of drugs across the skin into systemic circulation. They are particularly advantageous for drugs with short half-lives or narrow therapeutic indices, as they maintain consistent plasma concentrations and reduce the risk of subtherapeutic or toxic levels.TDDS are categorized into monolithic, reservoir, and mixed systems. Monolithic systems embed the drug in a polymer matrix, where diffusion governs release. Reservoir systems...
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...